Pronota and Molecuence announce collaboration in protein biomarker discovery

02-23-2011: Pronota NV announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke.  Pronota will apply its  proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification (MASSterclass™) to this project. The financial terms have not been disclosed.

“We’re finding potential collaborators are increasingly persuaded by our track record of not only being able to identify novel protein biomarkers, but also of taking these successfully through the verification process to show they are true, robust and clinically relevant discoveries.  We’re delighted to be working with Molecuence, who are one of the leaders in the field of protein biomarker development for diagnostic applications”, commented Nick McCooke, CEO of Pronota.